BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35533722)

  • 21. Double-positive CD4(+)CD8(+) Sézary syndrome: an unusual phenotype with an aggressive clinical course.
    Wu R; Zippin JH; Magro C
    Cutis; 2014 Feb; 93(2):E18-25. PubMed ID: 24605355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome).
    Cirée A; Michel L; Camilleri-Bröet S; Jean Louis F; Oster M; Flageul B; Senet P; Fossiez F; Fridman WH; Bachelez H; Tartour E
    Int J Cancer; 2004 Oct; 112(1):113-20. PubMed ID: 15305382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma.
    Zhang B; Cheng B; Li FS; Ding JH; Feng YY; Zhuo GZ; Wei HF; Zhao K
    Tumour Biol; 2015 Dec; 36(12):9411-9. PubMed ID: 26113408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells.
    Eriksen KW; Kaltoft K; Mikkelsen G; Nielsen M; Zhang Q; Geisler C; Nissen MH; Röpke C; Wasik MA; Odum N
    Leukemia; 2001 May; 15(5):787-93. PubMed ID: 11368440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel mouse model for Sézary syndrome using xenotransplantation of Sézary cells into immunodeficient RAG2(-/-) γc(-/-) mice.
    van der Fits L; Rebel HG; Out-Luiting JJ; Pouw SM; Smit F; Vermeer KG; van Zijl L; Tensen CP; Weijer K; Vermeer MH
    Exp Dermatol; 2012 Sep; 21(9):706-9. PubMed ID: 22897578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile.
    Saed G; Fivenson DP; Naidu Y; Nickoloff BJ
    J Invest Dermatol; 1994 Jul; 103(1):29-33. PubMed ID: 8027577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients.
    Schuler PJ; Schilling B; Harasymczuk M; Hoffmann TK; Johnson J; Lang S; Whiteside TL
    Eur J Immunol; 2012 Jul; 42(7):1876-85. PubMed ID: 22585562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dysfunctional CD39(POS) regulatory T cells and aberrant control of T-helper type 17 cells in autoimmune hepatitis.
    Grant CR; Liberal R; Holder BS; Cardone J; Ma Y; Robson SC; Mieli-Vergani G; Vergani D; Longhi MS
    Hepatology; 2014 Mar; 59(3):1007-15. PubMed ID: 23787765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells.
    Schuler PJ; Saze Z; Hong CS; Muller L; Gillespie DG; Cheng D; Harasymczuk M; Mandapathil M; Lang S; Jackson EK; Whiteside TL
    Clin Exp Immunol; 2014 Aug; 177(2):531-43. PubMed ID: 24749746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome.
    Zaki MH; Shane RB; Geng Y; Showe LC; Everetts SE; Presky DH; Wysocka M; Moore JS; Rook AH
    J Invest Dermatol; 2001 Jul; 117(1):119-27. PubMed ID: 11442758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
    Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
    Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulatory T cells regulate the distribution of natural killer T cells through CD39 signal transduction in asthma.
    Lu Y; Li Y; Zhou W; Ding B; Yu Q
    Hum Cell; 2019 Apr; 32(2):141-149. PubMed ID: 30539423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function.
    Nagate Y; Ezoe S; Fujita J; Okuzaki D; Motooka D; Ishibashi T; Ichii M; Tanimura A; Kurashige M; Morii E; Fukushima T; Suehiro Y; Yokota T; Shibayama H; Oritani K; Kanakura Y
    Leukemia; 2021 Jan; 35(1):107-118. PubMed ID: 32203145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
    Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IL-12 and IL-4 activate a CD39-dependent intrinsic peripheral tolerance mechanism in CD8(+) T cells.
    Noble A; Mehta H; Lovell A; Papaioannou E; Fairbanks L
    Eur J Immunol; 2016 Jun; 46(6):1438-48. PubMed ID: 26990545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined High-Throughput Approaches Reveal the Signals Driven by Skin and Blood Environments and Define the Tumor Heterogeneity in Sézary Syndrome.
    Cristofoletti C; Bresin A; Fioretti M; Russo G; Narducci MG
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.
    Bastid J; Regairaz A; Bonnefoy N; Déjou C; Giustiniani J; Laheurte C; Cochaud S; Laprevotte E; Funck-Brentano E; Hemon P; Gros L; Bec N; Larroque C; Alberici G; Bensussan A; Eliaou JF
    Cancer Immunol Res; 2015 Mar; 3(3):254-65. PubMed ID: 25403716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impaired proteasome function activates GATA3 in T cells and upregulates CTLA-4: relevance for Sézary syndrome.
    Gibson HM; Mishra A; Chan DV; Hake TS; Porcu P; Wong HK
    J Invest Dermatol; 2013 Jan; 133(1):249-57. PubMed ID: 22951729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice.
    Sun X; Wu Y; Gao W; Enjyoji K; Csizmadia E; Müller CE; Murakami T; Robson SC
    Gastroenterology; 2010 Sep; 139(3):1030-40. PubMed ID: 20546740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice.
    Bao R; Shui X; Hou J; Li J; Deng X; Zhu X; Yang T
    Int J Mol Med; 2016 Sep; 38(3):969-75. PubMed ID: 27430240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.